Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanistic insights into PROTAC-mediated degradation through an integrated framework of molecular dynamics, free energy landscapes, and quantum mechanics: A case study on kinase degraders. | J Comput Aided Mol Des | 2025 | 40665123 | PubTator, text mining | PubMed |
| Beyond the G-Loop: CRBN Molecular Glues Potently Target VAV1 via a Novel SH3 RT-Loop Degron. | bioRxiv | 2025 | 40661494 | PubTator, text mining | PubMed |
| Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines. | Biochem Pharmacol | 2025 | 40659131 | PubTator, text mining | PubMed |
| Serum Cereblon (CRBN) Levels Predict Long Term Post- Lenalidomide-Dexamethasone Survival in Multiple Myeloma (MM) Patients and Correlate with Disease Characteristics. | Int J Mol Sci | 2025 | 40650115 | PubTator, text mining | PubMed |
| Utilizing small molecules to probe and harness the proteome by pooled protein tagging with ligandable domains. | Front Pharmacol | 2025 | 40626313 | PubTator, text mining | PubMed |
| Site-resolved assessment of targeted protein degradation. | Cell Chem Biol | 2025 | 40614719 | PubTator, text mining | PubMed |
| A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma. | Blood Neoplasia | 2025 | 40612717 | PubTator, text mining | PubMed |
| Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition. | Science | 2025 | 40608931 | PubTator, text mining | PubMed |
| Design and Application of Cereblon-Recruiting Prodegraders. | J Am Chem Soc | 2025 | 40600467 | PubTator, text mining | PubMed |
| Chemical Proteomics Identifies RBBP7 as a New E3 Ligase Supporting Targeted Protein Degradation. | Angew Chem Int Ed Engl | 2025 | 40600340 | PubTator, text mining | PubMed |
| In situ construction of intracellular supramolecular assemblies as an alternative strategy for protein degradation. | Nat Commun | 2025 | 40595630 | PubTator, text mining | PubMed |
| Conditioned Generative Modeling of Molecular Glues: A Realistic AI Approach for Synthesizable Drug-like Molecules. | Biomolecules | 2025 | 40563489 | PubTator, text mining | PubMed |
| From Concepts to Inhibitors: A Blueprint for Targeting Protein-Protein Interactions. | Chem Rev | 2025 | 40553022 | PubTator, text mining | PubMed |
| High cereblon expression in neuroendocrine cancer confers vulnerability to GSPT1 molecular glue degrader. | Exp Hematol Oncol | 2025 | 40551250 | PubTator, text mining | PubMed |
| Investigation of Glutarimide N-Alkylated Derivatives of Lenalidomide. | ACS Chem Biol | 2025 | 40523848 | PubTator, text mining | PubMed |
| Targeted O-GlcNAcylation of CK2α Triggers Its Ubiquitin-Proteasome Degradation and Alters Downstream Phosphorylation. | ACS Chem Biol | 2025 | 40521680 | PubTator, text mining | PubMed |
| HADDOCK-Guided modeling and molecular simulations of cereblon-based ternary complexes: Development of novel PROTACs for Ataxia telangiectasia and RAD3-Related (ATR) kinase. | Comput Biol Med | 2025 | 40516451 | PubTator, text mining | PubMed |
| Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader. | RSC Med Chem | 2025 | 40510905 | PubTator, text mining | PubMed |
| Targeting programmed cell death with natural products: a potential therapeutic strategy for diminished ovarian reserve and fertility preservation. | Front Pharmacol | 2025 | 40510420 | PubTator, text mining | PubMed |
| Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor Degradation. | Cancers (Basel) | 2025 | 40507351 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=13